Organisation paid for research Program year 2025 Source: CMS Open Payments

Burke Primary Care, LLC

Neither a doctor nor a teaching hospital

Research payments

$840,420

564 payments

Through program year 2025, Burke Primary Care, LLC is reported as receiving $840,420 in research payments, across 564 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $54,507 1
2024 Research $9,619 7
2023 Research $144,221 87
2022 Research $140,006 36
2021 Research $167,621 187
2020 Research $259,034 128
2019 Research $65,413 118

Breakdown

Who paid Research payments · program years 2019–2025
  1. Novo Nordisk AS $663,321 551 payments
  2. AstraZeneca Pharmaceuticals LP $79,940 7 payments
  3. Novartis Pharmaceuticals Corporation $54,507 1 payment
  4. AstraZeneca UK Limited $29,744 2 payments
  5. Genentech, Inc. $11,084 1 payment
  6. Janssen Research & Development, LLC $1,824 2 payments
Studies the money was for Research payments · program years 2019–2025
  1. Ex9536-4388 $646,390 376 payments
  2. A Long Term Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh Cardiovascular Risk PatienTs with Hypertriglyceridemia $86,931 6 payments
  3. A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients $54,507 1 payment
  4. Nn9535-4321 $16,930 175 payments
  5. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $12,237 1 payment
  6. Transmission Study Household $11,084 1 payment
  7. A Multinational Randomised Double Blind Placebo Controlled Trial to Evaluate the Effect of Ticagrelor 90 mg twice daily on the Incidence of Cardiovascular Death Myocardial Infarction or Stroke in Patients with Type 2 Diabetes $8,833 1 payment
  8. A Randomized Double Blind, Placebo Group, Two-Arm, Multicenter study to Assess Efficacy of Canagliflozin on End Stage Kidney Disease and Vascular Death in Subjects with Type 2 Diabetes Mellitus and nephropathy $1,824 2 payments
  9. A Randomized, Double Blind, Placebo Controlled, Multicenter, Parallel Group, Dose Ranging Study to Evaluate CIN 107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease $1,683 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record